Curasight: Brain cancer as first indication in uTREAT study
Back in February 2024, Curasight adopted a new strategy centered around a Theranostic approach (uTREAT – therapy/treatment and uPAR – diagnostic) for its various disease areas. Curasight selected the following five key areas for a basket trial:
- Brain cancer (Glioblastoma)
- Neuroendocrine tumors (NET)
- Head-and-neck cancer (HNSCC)
- Non-small cell lung cancer (NSCLC)
- Pancreatic cancer
In conjunction with the company’s Q2 report, Curasight presented a detailed milestone plan (upcoming triggers) to allow investors to track the company’s progress.
It is clear that investors can expect updates on the last enrolled patient in the Phase II trial for uTRACE in prostate cancer, conducted in partnership with Curium. Additionally, investors will receive preliminary data on the overall uTRACE study, followed by the selection of a "Proof-of-Concept" candidate for the pilot study under the company’s theranostic strategy.
Data from the study was published last week in the prestigious journal EJNMMI Research (European Journal of Nuclear Medicine and Molecular Imaging), with the following highlights:
- The study included 24 patients with brain cancer.
- Among these 24 patients, 16 (67%) were diagnosed with WHO grade 4 gliomas, 6 (25%) with grade 3, and 2 (8%) with grade 2.
- Nearly all (94%) of the grade 4 gliomas (glioblastomas) were uPAR-PET positive.
- At a median follow-up of 18.8 months (range: 2.1–45.6 months), 19 patients experienced disease progression, and 14 had died.
- The authors conclude that "The majority of glioma patients, and almost all with grade 4 gliomas, displayed uPAR-positive lesions" and that "High uPAR expression is significantly correlated with worse survival outcomes for patients."
Based on the promising uPAR data in brain cancer, this disease area has been selected as the "Proof-of-Concept." Brain cancer, particularly grade 4 gliomas, currently has no available treatment and is associated with very high mortality, as reflected in the data above.
In 2024, Curasight has worked to secure its capital readiness, which was partially achieved during the summer and fall of 2024 through a directed issuance and subscription rights in units consisting of TO2+TO3, with the latter being oversubscribed. The first warrant program (TO2) will begin in December 2024.
Using warrant programs related to different share price levels is always associated with uncertainty, but with the latest highly convincing data and a clear strategy, we see a reduced risk for the first program.
We focus on the recently published data and invite you to an Deep Dive event with the company’s management on Friday, November 15, at 13:00 – register here:
Deep Dive in Brain Cancer event
Additionally, we will hold the company’s Q3 event on November 25, and registration can be done here:
Disclaimer: HC Andersen Capital receives payment from Curasight for a DigitalIR/Corporate Visibility and IR advisory agreement. /Claus Thestrup 12/11 2024 at 08:10.